Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis

Molecular Oncology

Volumn 10, Issue 8, 2016, Pages 1305-1316

  Gerdtsson, Anna Sandström ^a   Wingren, Christer ^a   Persson, Helena ^a   Delfani, Payam ^a   Nordström, Malin ^b   Ren, He ^c   Wen, Xin ^c   Ringdahl, Ulrika ^a   Borrebaeck, Carl A K ^a   Hao, Jihui ^c  

^a LUND UNIVERSITY   (Sweden)

^b Immunovia AB   (Sweden)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Antibody microarrays; Biomarker signatures; Early detection; Pancreatic cancer; Recombinant antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; PLASMA PROTEIN; RECOMBINANT ANTIBODY; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUPPORT VECTOR MACHINE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CASE CONTROL STUDY; CAUCASIAN; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROTEOMICS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; BLOOD PROTEINS; CASE-CONTROL STUDIES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; YOUNG ADULT;

EID: 84981747462     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2016.07.001     Document Type: Article

References (60)

1. Alonzo, T.A., Pepe, M.S., Moskowitz, C.S., Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat. Med. 21 (2002), 835–852.
2. Bauden, M., Pamart, D., Ansari, D., Herzog, M., Eccleston, M., Micallef, J., Andersson, B., Andersson, R., Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin. Epigenetics, 7, 2015, 106.
3. Bellone, G., Smirne, C., Mauri, F.A., Tonel, E., Carbone, A., Buffolino, A., Dughera, L., Robecchi, A., Pirisi, M., Emanuelli, G., Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol. Immunother. 55 (2006), 684–698.
4. Borrebaeck, C.A., Wingren, C., Recombinant antibodies for the generation of antibody arrays. Methods Mol. Biol. 785 (2011), 247–262.
5. Brand, R.E., Nolen, B.M., Zeh, H.J., Allen, P.J., Eloubeidi, M.A., Goldberg, M., Elton, E., Arnoletti, J.P., Christein, J.D., Vickers, S.M., Langmead, C.J., Landsittel, D.P., Whitcomb, D.C., Grizzle, W.E., Lokshin, A.E., Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 17 (2011), 805–816.
6. Bunger, S., Laubert, T., Roblick, U.J., Habermann, J.K., Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J. Cancer Res. Clin. Oncol. 137 (2011), 375–389.
7. Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldertorp, B., Ferno, M., Olsson, H., Borrebaeck, C.A., Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer 44 (2008), 472–480.
8. Carlsson, A., Wingren, C., Kristensson, M., Rose, C., Ferno, M., Olsson, H., Jernstrom, H., Ek, S., Gustavsson, E., Ingvar, C., Ohlsson, M., Peterson, C., Borrebaeck, C.A., Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc. Natl. Acad. Sci. U. S. A 108 (2011), 14252–14257.
9. Carlsson, A., Wuttge, D.M., Ingvarsson, J., Bengtsson, A.A., Sturfelt, G., Borrebaeck, C.A., Wingren, C., Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol. Cell. Proteomics, 10, 2011 M110 005033.
10. Chen, J., Wu, W., Zhen, C., Zhou, H., Yang, R., Chen, L., Hu, L., Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncol. Lett. 6 (2013), 43–48.
11. Conlon, K.C., Klimstra, D.S., Brennan, M.F., Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg. 223 (1996), 273–279.
12. Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
13. Dexlin-Mellby, L., Sandstrom, A., Centlow, M., Nygren, S., Hansson, S.R., Borrebaeck, C.A., Wingren, C., Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays. Proteomics Clin. Appl. 4 (2010), 794–807.
14. Eyigor, C., Karaca, B., Kuzeyli-Yildirim, Y., Uslu, R., Uyar, M., Coker, A., Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain?. J. B.U.ON. 15 (2010), 543–546.
15. Feldmann, G., Mishra, A., Bisht, S., Karikari, C., Garrido-Laguna, I., Rasheed, Z., Ottenhof, N.A., Dadon, T., Alvarez, H., Fendrich, V., Rajeshkumar, N.V., Matsui, W., Brossart, P., Hidalgo, M., Bannerji, R., Maitra, A., Nelkin, B.D., Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol. Ther. 12 (2011), 598–609.
16. Furukawa, H., Okada, S., Saisho, H., Ariyama, J., Karasawa, E., Nakaizumi, A., Nakazawa, S., Murakami, K., Kakizoe, T., Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 78 (1996), 986–990.
17. Gabitass, R.F., Annels, N.E., Stocken, D.D., Pandha, H.A., Middleton, G.W., Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60 (2011), 1419–1430.
18. Gangi, S., Fletcher, J.G., Nathan, M.A., Christensen, J.A., Harmsen, W.S., Crownhart, B.S., Chari, S.T., Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR. Am. J. Roentgenol 182 (2004), 897–903.
19. Gerdtsson, A.S., Malats, N., Säll, A., Real, F.X., Porta, M., Skoog, P., Persson, H., Wingren, C., Borrebaeck, C.A.K., A multicenter trial defining a serum protein signature associated with pancreatic ductal adenocarcinoma. Int. J. Proteomics, 2015, 2015.
20. Gupta, S., Venkatesh, A., Ray, S., Srivastava, S., Challenges and prospects for biomarker research: a current perspective from the developing world. Biochim. Biophys. Acta 1844 (2014), 899–908.
21. Gustavsson, E., Ek, S., Steen, J., Kristensson, M., Algenas, C., Uhlen, M., Wingren, C., Ottosson, J., Hober, S., Borrebaeck, C.A., Surrogate antigens as targets for proteome-wide binder selection. New Biotechnol. 28 (2011), 302–311.
22. Haab, B.B., Geierstanger, B.H., Michailidis, G., Vitzthum, F., Forrester, S., Okon, R., Saviranta, P., Brinker, A., Sorette, M., Perlee, L., Suresh, S., Drwal, G., Adkins, J.N., Omenn, G.S., Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 5 (2005), 3278–3291.
23. Honda, K., Okusaka, T., Felix, K., Nakamori, S., Sata, N., Nagai, H., Ioka, T., Tsuchida, A., Shimahara, T., Shimahara, M., Yasunami, Y., Kuwabara, H., Sakuma, T., Otsuka, Y., Ota, N., Shitashige, M., Kosuge, T., Buchler, M.W., Yamada, T., Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLoS One, 7, 2012, e46908.
24. Hou, J., Xu, J., Jiang, R., Wang, Y., Chen, C., Deng, L., Huang, X., Wang, X., Sun, B., Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology 57 (2013), 678–688.
25. Huang, Y.T., Li, F.F., Ke, C., Li, Z., Li, Z.T., Zou, X.F., Zheng, X.X., Chen, Y.P., Zhang, H., PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J. Transl Med., 11, 2013, 245.
26. Ingvarsson, J., Larsson, A., Sjoholm, A.G., Truedsson, L., Jansson, B., Borrebaeck, C.A., Wingren, C., Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J. Proteome Res. 6 (2007), 3527–3536.
27. Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P., Wahren, B., Engstrom, G., Harmenberg, U., Krogh, M., Peterson, C., Borrebaeck, C.A., Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 8 (2008), 2211–2219.
28. Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Buchler, M.W., Korc, M., Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 3 (1997), 1309–1316.
29. Jimenez-Vidal, M., Srivastava, J., Putney, L.K., Barber, D.L., Nuclear-localized calcineurin homologous protein CHP1 interacts with upstream binding factor and inhibits ribosomal RNA synthesis. J. Biol. Chem. 285 (2010), 36260–36266.
30. Jin, Q., Kong, B., Yang, X., Cui, B., Wei, Y., Yang, Q., Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer. In Vivo 21 (2007), 593–598.
31. Johnson, W.E., Li, C., Rabinovic, A., Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 (2007), 118–127.
32. Kristensson, M., Olsson, K., Carlson, J., Wullt, B., Sturfelt, G., Borrebaeck, C.A., Wingren, C., Design of recombinant antibody microarrays for urinary proteomics. Proteomics Clin. Appl. 6 (2012), 291–296.
33. Lau, M.K., Davila, J.A., Shaib, Y.H., Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39 (2010), 458–462.
34. Ling, Q., Xu, X., Zheng, S.S., Kalthoff, H., The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobiliary Pancreat Dis Int 12 (2013), 480–487.
35. Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., Macdonald, J.S., Somerfield, M.R., Hayes, D.F., Bast, R.C. Jr., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24 (2006), 5313–5327.
36. Melo, S.A., Luecke, L.B., Kahlert, C., Fernandez, A.F., Gammon, S.T., Kaye, J., LeBleu, V.S., Mittendorf, E.A., Weitz, J., Rahbari, N., Reissfelder, C., Pilarsky, C., Fraga, M.F., Piwnica-Worms, D., Kalluri, R., Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523 (2015), 177–182.
37. Motiwala, T., Kutay, H., Ghoshal, K., Bai, S., Seimiya, H., Tsuruo, T., Suster, S., Morrison, C., Jacob, S.T., Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13844–13849.
38. Pannala, R., Basu, A., Petersen, G.M., Chari, S.T., New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 10 (2009), 88–95.
39. Pauly, F., Dexlin-Mellby, L., Ek, S., Ohlin, M., Olsson, N., Jirstrom, K., Dictor, M., Schoenmakers, S., Borrebaeck, C.A., Wingren, C., Protein expression profiling of formalin-fixed paraffin-embedded tissue using recombinant antibody microarrays. J. Proteome Res. 12 (2013), 5943–5953.
40. Pauly, F., Smedby, K.E., Jerkeman, M., Hjalgrim, H., Ohlsson, M., Rosenquist, R., Borrebaeck, C.A., Wingren, C., Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. Leuk. Res. 38 (2014), 682–690.
41. Pelaez-Luna, M., Takahashi, N., Fletcher, J.G., Chari, S.T., Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am. J. Gastroenterol. 102 (2007), 2157–2163.
42. Rastogi, T., Hildesheim, A., Sinha, R., Opportunities for cancer epidemiology in developing countries. Nature reviews. Cancer 4 (2004), 909–917.
43. Säll, A., Walle, M., Wingren, C., Müller, S., Nyman, T., Vala, A., Ohlin, M., Borrebaeck, C.A.K., Persson, H., Generation and analyses of human synthetic antibody libraries and their application for protein microarrays. Protein Eng Des Sel, 2016 (in press).
44. Sandstrom, A., Andersson, R., Segersvard, R., Lohr, M., Borrebaeck, C.A., Wingren, C., Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals disease-associated biomarker signatures. Proteomics Clin. Appl. 6 (2012), 486–496.
45. Shaw, V.E., Lane, B., Jenkinson, C., Cox, T., Greenhalf, W., Halloran, C.M., Tang, J., Sutton, R., Neoptolemos, J.P., Costello, E., Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol. Cancer, 13, 2014, 114.
46. Shimizu, Y., Yasui, K., Matsueda, K., Yanagisawa, A., Yamao, K., Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J. Gastroenterol. Hepatol. 20 (2005), 1591–1594.
47. Soderlind, E., Strandberg, L., Jirholt, P., Kobayashi, N., Alexeiva, V., Aberg, A.M., Nilsson, A., Jansson, B., Ohlin, M., Wingren, C., Danielsson, L., Carlsson, R., Borrebaeck, C.A., Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat. Biotechnol. 18 (2000), 852–856.
48. Sohn, T.A., Yeo, C.J., Cameron, J.L., Koniaris, L., Kaushal, S., Abrams, R.A., Sauter, P.K., Coleman, J., Hruban, R.H., Lillemoe, K.D., Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4 (2000), 567–579.
49. Song, M.S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., Pandolfi, P.P., The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455 (2008), 813–817.
50. Stoevesandt, O., Taussig, M.J., European and international collaboration in affinity proteomics. New Biotechnol. 29 (2012), 511–514.
51. Surinova, S., Schiess, R., Huttenhain, R., Cerciello, F., Wollscheid, B., Aebersold, R., On the development of plasma protein biomarkers. J. Proteome Res. 10 (2011), 5–16.
52. Watanabe, I., Sasaki, S., Konishi, M., Nakagohri, T., Inoue, K., Oda, T., Kinoshita, T., Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 28 (2004), 160–165.
53. Wingren, C., Ingvarsson, J., Dexlin, L., Szul, D., Borrebaeck, C.A., Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics 7 (2007), 3055–3065.
54. Wingren, C., Sandstrom, A., Segersvard, R., Carlsson, A., Andersson, R., Lohr, M., Borrebaeck, C.A., Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 72 (2012), 2481–2490.
55. Winter, J.M., Tang, L.H., Klimstra, D.S., Brennan, M.F., Brody, J.R., Rocha, F.G., Jia, X., Qin, L.X., D'Angelica, M.I., DeMatteo, R.P., Fong, Y., Jarnagin, W.R., O'Reilly, E.M., Allen, P.J., A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One, 7, 2012, e40157.
56. Wu, T.C., Shao, Y.F., Shan, Y., Wu, J.X., Zhao, P., [Surgical effect of malignant tumor of body and tail of the pancreas: compare with pancreatic head cancer]. Zhonghua Wai Ke Za Zhi 45 (2007), 30–33.
57. Xia, C., Ma, W., Stafford, L.J., Liu, C., Gong, L., Martin, J.F., Liu, M., GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins. Mol. Cell. Biol. 23 (2003), 2476–2488.
58. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R.H., Eshleman, J.R., Nowak, M.A., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Iacobuzio-Donahue, C.A., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 (2010), 1114–1117.
59. Zhang, Q., Zeng, L., Chen, Y., Lian, G., Qian, C., Chen, S., Li, J., Huang, K., Pancreatic cancer epidemiology, detection, and management. Gastroenterol. Res. Pract., 2016, 2016, 8962321.
60. Zhao, G.Y., Lin, Z.W., Lu, C.L., Gu, J., Yuan, Y.F., Xu, F.K., Liu, R.H., Ge, D., Ding, J.Y., USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. Tumour Biol. 36:3 (2015 Mar), 1721–1729.